期刊文献+

表达前列腺特异性膜抗原的DNA疫苗对肿瘤细胞的抑制作用 被引量:2

DNA vaccine expressing PSMA elicits suppresses tumor cells
原文传递
导出
摘要 目的构建表达前列腺特异性膜抗原(PSMA)的DNA疫苗,观察其在体外对肿瘤细胞的免疫攻击和在体内对肿瘤细胞攻击的免疫保护作用。方法通过稳定转染构建表达PSMA的小鼠黑色素瘤细胞系B16-PSMA,将DNA疫苗pCDNA3.1-PSMA通过肌肉注射导入C57BL/6小鼠体内,分离小鼠脾细胞,检测细胞毒性T淋巴细胞(cytotoxicTlymphocytes,CTL)反应。以B16-PSMA细胞攻击免疫后小鼠,观察免疫动物的无瘤生存期和肿瘤体积增长情况,评价DNA疫苗的抗肿瘤作用。结果DNA疫苗可诱导小鼠脾淋巴细胞CTL活性,经过免疫后的小鼠成瘤率降低,无瘤生存期延长,肿瘤生长缓慢,肿瘤组织内有较多淋巴细胞浸润,表明产生较强的抗肿瘤反应。结论表达PSMA的DNA疫苗能够诱导小鼠产生特异性免疫反应,对表达PSMA的肿瘤细胞的攻击产生免疫保护作用,为前列腺癌的预防和免疫治疗提供了新的思路。 Objective To construct DNA vaccine expressing PSMA(prostate specific membrane antigen) and to investigate its suppression to tumor cells. Methods An eukaryotic expression vector pCDNA3.1-PSMA encoding full-length PSMA cDNA was constructed, and was introduced into B16 cells to establish a PSMA-expressing murine melanoma B16-PSMA cell line. Tile C57BL/6 mice were immunized with DNA vaccine pCDNA3.1-PSMA by intramuscular injection. After four dosages of immunizations, splenocytes were isolated and stimulated by mitomycin-treated B16-cells, cytotoxic T lymphocytes(CTL) activity was measured by lactate dehydrogenase(LDH) release method. The immunized C57BL/6 mice were also challenged by transplanting B16-PSMA cells, tumor-free survival time and the growth rate of tumors were recorded to investigate the anti-tumor reacfon. Results DNA vaccine expressing PSMA elicited CTL reaction of splenocytes. After DNA vaccine immunization, tumor occurence reduced and tumor-free time was prolonged. Although tumors developed in immunized mice, the growth speed of the tumors was markedly reduced. Histological examination showed that there was infdtrafion by lymphoeytes in tumors from immunized mice, while this infiltration was less prominent in control group. Conclusion DNA vaccine expressing PSMA induced specific cellular immune response and suppressed tumor cells, that may provide a potential alternative in the treatment of carcinoma of prostate.
出处 《中华微生物学和免疫学杂志》 CAS CSCD 北大核心 2005年第7期570-573,共4页 Chinese Journal of Microbiology and Immunology
  • 相关文献

参考文献15

  • 1Israeli RS, Powell CT, Corr JG, et al. Expression of the prostate-specific membrane antigen. Cancer Res, 1994, 54: 1807-1811.
  • 2Kawakami M, Nakayama J. Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res, 1997, 57: 2321-2324.
  • 3Xiao Z, Adam BL, Cazares LH, et al. Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res, 2001, 61: 6029-6033.
  • 4Wright GL Jr, Grob BM, Haley C, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology, 1996, 48: 326-334.
  • 5Silver DA, Pellicer I, Fair WR, et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res, 1997, 3: 81-85.
  • 6任加强,郑莉,陈琦,李华,张敏,张膺宇,张秀荣,朱虹光.抗PSMA膜外段单克隆抗体的制备及其初步应用[J].复旦学报(医学版),2003,30(4):330-332. 被引量:3
  • 7Boyd D, Hung CF, Wu TC. DNA vaccines for cancer. Idrugs, 2003, 6: 1155-1164.
  • 8Bhattachary R, Bukkapatnam R, Prawoko I, et al. Efficacy of vaccination with plasmid DNA encoding for HER2/neu or HER2/neu-eGFP fusion protein against prostate cancer in rats. Int Immunopharmacol, 2002, 2: 783-796.
  • 9Mincheff M, Zoubak S, Altankova I, et al. Human dendritic cells genetically engineered to express cytosolically retained fragment of prostate-specific membrane antigen prime cytotoxic T-cell responses to multiple epitopes. Cancer Gene Ther, 2003, 10: 907-917.
  • 10Murphy GP, Tjoa BA, Simmons SJ, et al. Higher-dose and less frequent dendritic cell infusions with PSMA peptides in hormone-refractory metastatic prostate cancer patients. Prostate, 2000, 43: 59-62.

二级参考文献9

  • 1Bostwick DG, Pacelli A, Blute M, et al. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma:a study of 184 cases. Cancer, 1998,82:2256.
  • 2Sweat SD, Pacelli A, Murphy GP, et al. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology, 1998,52:637.
  • 3Xiao Z, Adam BL, Cazares LH, et al. Quantitation of serum prostatespecific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res,2001,61 : 6029.
  • 4Douglas TH, Morgan TO, MeLeod DG, et al. Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients.Cancer, 1997,80:107.
  • 5Murphy GP, Barren RJ, Erickson SJ, et al. Evaluation and comparison of two new prostate carcinoma markers: Free-prostate specific antigen and prostate specific membrane antigen. Cancer, 1996,78:8O9.
  • 6Liu H, Rajasekaran AK, Moy P, et al. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res, 1998,58:4055.
  • 7Fracasso G,Bellisola G,Cingarlini S, et al. Anti-tumor effects of toxins targeted to the prostate specific membrane antigen. Prostate,2002,53:9.
  • 8Ballangrud AM, Yang WH, Charlton D, et al. Response of LNCaP spheroids after treatment with an alpha-particle emitter (213Bi)-labeled anti-prostate-specific membrane antigen antibody(J591).Cancer Res ,2001,61:2008.
  • 9McDevitt MR,Barendswaard E, Ma D, et al. An alpha-particle emitting antibody( [^213Bi]J591 ) for radioimmunotherapy of prostate cancer. Cancer Res, 2000,60 : 6095.

共引文献2

同被引文献8

引证文献2

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部